Du Lijing, Sun Yuanfang, Gan Yu, Wang Leqi, Li Xinyi, Yan Shikai, Xiao Xue, Li Shasha, Jin Huizi
Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs, School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.
The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Ann Med. 2025 Dec;57(1):2499700. doi: 10.1080/07853890.2025.2499700. Epub 2025 May 8.
Bunge oil (XSBO) has garnered significant interest from researchers due to its distinctive anti-Alzheimer's disease (AD) properties. However, the underlying molecular mechanism remain unclear. This study aims to investigate the potential mechanisms by which XSBO may exert therapeutic effects on AD by employing a combination of network pharmacology analysis and experimental validation.
The chemical composition and absorbed compounds of XSBO were identified using GC-MS and LC-MS. Network pharmacology analysis was performed using various computational tools to identify hub genes and construct compound-target-pathway networks. Subsequently, both and experiments were conducted to confirm the mechanisms by which XSBO may treat AD.
The results identified 43 active compounds in XSBO, targeting a total of 223 genes, of which 191 were associated with AD. Network analysis indicated that the active constituents in XSBO, such as 9,12-octadecadienoic acid, linoelaidic acid and 11-octadecenoic acid, interact with targets including MAPK1, MAPK3, AKT1, RXRA, RXRB, PPARD and PPARA to modulate inflammation-related signalling pathways and the sphingolipid signalling pathway. investigations corroborated that XSBO can significantly influence the viability of Aβ25-35-induced SH-SY5Y cells the MAPK pathway.
This study demonstrated that XSBO has the potential to mitigate inflammation network disorders through the MAPK pathway and to restore sphingolipid metabolite levels in AD rats, thereby laying a groundwork for future studies.
由于其独特的抗阿尔茨海默病（AD）特性，紫苏油（XSBO）引起了研究人员的极大兴趣。然而，其潜在的分子机制仍不清楚。本研究旨在通过网络药理学分析和实验验证相结合的方法，探讨XSBO对AD发挥治疗作用的潜在机制。
采用气相色谱-质谱联用（GC-MS）和液相色谱-质谱联用（LC-MS）技术鉴定XSBO的化学成分和吸收的化合物。使用各种计算工具进行网络药理学分析，以识别枢纽基因并构建化合物-靶点-通路网络。随后，进行了细胞实验和动物实验，以证实XSBO治疗AD的机制。
结果鉴定出XSBO中的43种活性化合物，共靶向223个基因，其中191个与AD相关。网络分析表明，XSBO中的活性成分，如9,12-十八碳二烯酸、反式-9,12-十八碳二烯酸和11-十八碳烯酸，与包括丝裂原活化蛋白激酶1（MAPK1）、丝裂原活化蛋白激酶3（MAPK3）、蛋白激酶B（AKT1）、视黄酸X受体α（RXRA）、视黄酸X受体β（RXRB）、过氧化物酶体增殖物激活受体δ（PPARD）和过氧化物酶体增殖物激活受体α（PPARA）在内的靶点相互作用，以调节炎症相关信号通路和鞘脂信号通路。细胞实验证实，XSBO可通过MAPK途径显著影响Aβ25-35诱导的SH-SY5Y细胞的活力。
本研究表明，XSBO有潜力通过MAPK途径减轻AD大鼠的炎症网络紊乱，并恢复鞘脂代谢产物水平，从而为未来的研究奠定基础。
